Actively Recruiting
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Led by AbbVie · Updated on 2026-04-28
16
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel.
CONDITIONS
Official Title
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Laboratory values meet the criteria specified in the protocol.
- General good health based on medical history, physical exam, vital signs, laboratory tests, and ECG.
You will not qualify if you...
- History of significant illness, infection, major fever, hospitalization, or surgery within 30 days before the first study dose.
- Consumption of alcohol, grapefruit products, Seville oranges, starfruit products, or quinine/tonic water within 72 hours before study treatment.
- Use of tobacco or nicotine products within 3 months before the first study dose.
- Prior exposure to ABBV-722 within 90 days before the first study dose.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Acpru /Id# 281745
Grayslake, Illinois, United States, 60030
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here